Gothenburg, Sweden, September 14, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the United States Patent and Trademark Office (USPTO) intends to grant a patent relating to the Company's CD70-technology.
- This further improves our already strong IP portfolio. The decision from the United States Patent and Trademark Office, USPTO, gives us important protection for our CD70-technology, says Jamal El-Mosleh, CEO of Immunicum.
The US patent to be granted, with the title "Method for proliferation of antigen-specific T cells", protects the method for expansion of tumor specific T cells for so called adoptive immunotherapy with CAR T cells.
For more information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: jamal.el-mosleh@immunicum.com
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of
tumor diseases. A phase II clinical trial for the Company's most advanced
product - INTUVAX® against kidney cancer - has been initiated. The project
portfolio contains additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier. www.immunicum.se
The company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
www.redeye.se
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on September 14, 2016 at 14.00 CET.